Compile Data Set for Download or QSAR
maximum 50k data
Found 63 with Last Name = 'hong' and Initial = 'yr'
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340036(1-(3-chloro-2,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0500nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340037(1-(2-chloro-3,6-difluorophenyl)-3-(3-fluoro- 4-(7-...)
Affinity DataIC50:  0.0700nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340031(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.100nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340033(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.280nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340032(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.400nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340030(1-(2-chloro-6-fluoro-phenyl)-3-{3-fluoro-4- [7-(5-...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340039(1-{3-fluoro-4-[7-(5-methyl-1H-imidazol-2- yl)-1-ox...)
Affinity DataIC50:  0.900nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340029(1-(2,6-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  1nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340038(1-(4-chloro-2,6-difluoro-phenyl)-3-{3- fluoro-4-[7...)
Affinity DataIC50:  4nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340035(1-(4-cyano-3-fluorophenyl)-3-(3-fluoro-4- (7-(5-me...)
Affinity DataIC50:  5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340035(1-(4-cyano-3-fluorophenyl)-3-(3-fluoro-4- (7-(5-me...)
Affinity DataIC50:  5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340035(1-(4-cyano-3-fluorophenyl)-3-(3-fluoro-4- (7-(5-me...)
Affinity DataIC50:  5nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340034(1-(3,4-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  5.60nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340034(1-(3,4-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  5.60nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Crystalgenomics

US Patent
LigandPNGBDBM340034(1-(3,4-difluoro-phenyl)-3-{3-fluoro-4-[7-(5- methy...)
Affinity DataIC50:  5.60nMAssay Description:In order to evaluate the activity of the compounds of the present invention as a BTK inhibitor, commercially available BTK (Promega) was used for thi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50044996(CHEMBL3310408)
Affinity DataIC50:  400nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045003(CHEMBL3310402)
Affinity DataIC50:  700nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50441530(CHEMBL2436938)
Affinity DataIC50:  700nMAssay Description:Inhibition of PHD2 (unknown origin) after 30 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045002(CHEMBL3310403)
Affinity DataIC50:  800nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045006(CHEMBL3309273)
Affinity DataIC50:  1.20E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50044999(CHEMBL3310405)
Affinity DataIC50:  1.40E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50441531(CHEMBL2436937)
Affinity DataIC50:  1.50E+3nMAssay Description:Inhibition of PHD2 (unknown origin) after 30 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50441532(CHEMBL2436936)
Affinity DataIC50:  1.90E+3nMAssay Description:Inhibition of PHD2 (unknown origin) after 30 mins by fluorescence polarization assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50044998(CHEMBL3310406)
Affinity DataIC50:  2.00E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045031(CHEMBL3310397)
Affinity DataIC50:  2.10E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045042(CHEMBL3310393)
Affinity DataIC50:  2.20E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045030(CHEMBL3310398)
Affinity DataIC50:  2.40E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045034(CHEMBL3310396)
Affinity DataIC50:  2.60E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045038(CHEMBL3310395)
Affinity DataIC50:  2.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045020(CHEMBL3310400)
Affinity DataIC50:  3.00E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50045029(CHEMBL3310399)
Affinity DataIC50:  3.40E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetEgl nine homolog 1(Homo sapiens (Human))
Sungkyunkwan University

Curated by ChEMBL
LigandPNGBDBM50044997(CHEMBL3310407)
Affinity DataIC50:  3.80E+3nMAssay Description:Inhibition of PHD2 in human Hep3B cells assessed as erythropoietin secretion by ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 63 total ) | Next | Last >>
Jump to: